These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. Hou W; Janech MG; Sobolesky PM; Bland AM; Samsuddin S; Alazawi W; Syn WK Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31860081 [TBL] [Abstract][Full Text] [Related]
3. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD. Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973 [TBL] [Abstract][Full Text] [Related]
4. Candidate proteomic biomarkers for non-alcoholic fatty liver disease (steatosis and non-alcoholic steatohepatitis) discovered with mass-spectrometry: a systematic review. Lădaru A; Bălănescu P; Stan M; Codreanu I; Anca IA Biomarkers; 2016; 21(2):102-14. PubMed ID: 26632636 [TBL] [Abstract][Full Text] [Related]
5. Elevation of plasma tRNA fragments as a promising biomarker for liver fibrosis in nonalcoholic fatty liver disease. Huang P; Tu B; Liao HJ; Huang FZ; Li ZZ; Zhu KY; Dai F; Liu HZ; Zhang TY; Sun CZ Sci Rep; 2021 Mar; 11(1):5886. PubMed ID: 33723340 [TBL] [Abstract][Full Text] [Related]
15. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. Povero D; Eguchi A; Li H; Johnson CD; Papouchado BG; Wree A; Messer K; Feldstein AE PLoS One; 2014; 9(12):e113651. PubMed ID: 25470250 [TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients. Yuan XX; Zhu HJ; Pan H; Chen S; Liu ZY; Li Y; Wang LJ; Lu L; Yang HB; Gong FY World J Gastroenterol; 2019 Apr; 25(14):1741-1752. PubMed ID: 31011258 [TBL] [Abstract][Full Text] [Related]
17. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. Lefere S; Van de Velde F; Devisscher L; Bekaert M; Raevens S; Verhelst X; Van Nieuwenhove Y; Praet M; Hoorens A; Van Steenkiste C; Van Vlierberghe H; Lapauw B; Geerts A Int J Obes (Lond); 2017 Aug; 41(8):1207-1213. PubMed ID: 28461687 [TBL] [Abstract][Full Text] [Related]
18. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Kumagai E; Mano Y; Yoshio S; Shoji H; Sugiyama M; Korenaga M; Ishida T; Arai T; Itokawa N; Atsukawa M; Hyogo H; Chayama K; Ohashi T; Ito K; Yoneda M; Kawaguchi T; Torimura T; Nozaki Y; Watanabe S; Mizokami M; Kanto T Sci Rep; 2016 Oct; 6():35282. PubMed ID: 27739482 [TBL] [Abstract][Full Text] [Related]
19. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959 [TBL] [Abstract][Full Text] [Related]
20. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Li BH; He FP; Yang X; Chen YW; Fan JG Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]